Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Brellier, Florence ^a   Martina, Enrico ^a,b,f   Degen, Martin ^a,b,f   Heuzé Vourch, Nathalie ^c,d   Petit, Agnès ^d   Kryza, Thomas ^c,d   Courty, Yves ^d   Terracciano, Luigi ^e   Ruiz, Christian ^e   Chiquet Ehrismann, Ruth ^a,b  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITÉ DE TOURS   (France)

^d Université Franaois Rabelais   (France)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; SCLEROPROTEIN; TENASCIN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EPIDERMIS CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER; LUNG CARCINOMA; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MELANOMA; MOLECULAR WEIGHT; PANCREAS CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPLEEN; TISSUE MICROARRAY; TUMOR LOCALIZATION;

EID: 84865640095     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-14     Document Type: Article

References (35)

1. Cancer invasion and the microenvironment: plasticity and reciprocity. Friedl P, Alexander S, Cell 2011 147 992 1009 10.1016/j.cell.2011.11.016 22118458
2. How do tenascins influence the birth and life of a malignant cell? Brellier F, Chiquet-Ehrismann R, J Cell Mol Med 2012 16 32 40 10.1111/j.1582-4934.2011.01360.x 21692981
3. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
4. Why dont we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Bissell m, Hines WC, Nat Med 2011 17 320 329 10.1038/nm.2328 21383745
5. Tenascins and the importance of adhesion modulation. Chiquet-Ehrismann R, Tucker RP, Cold Spring Harb Perspect Biol 2011 3 004960 10.1101/cshperspect. a004960 21441591
6. Tenascin-W: an extracellular matrix protein associated with osteogenesis and cancer. Martina e, Chiquet-Ehrismann R, Brellier F, Int J Biochem Cell Biol 2010 42 1412 1415 10.1016/j.biocel.2010.06.004 20541035
7. Tenascins: regulation and putative functions during pathological stress. Chiquet-Ehrismann R, Chiquet M, J Pathol 2003 200 488 499 10.1002/path.1415 12845616 (Pubitemid 36818249)
8. The role of tenascin-C in tissue injury and tumorigenesis. Midwood KS, Orend G, J Cell Commun Signal 2009 3 287 310 10.1007/s12079-009-0075-1 19838819
9. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, Sakakura T, Proc Natl Acad Sci U S A 1987 84 4621 4625 10.1073/pnas.84.13. 4621 2440026
10. Tenascin-C induced signaling in cancer. Orend G, Chiquet-Ehrismann R, Cancer Lett 2006 244 143 163 10.1016/j.canlet.2006.02.017 16632194 (Pubitemid 44508708)
11. Advances in tenascin-C biology. Cellular and molecular life sciences. Midwood KS, Hussenet T, Langlois B, Orend G, CMLS 2011 68 3175 3199 10.1007/s00018-011-0783-6 21818551
12. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Schliemann S, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D, Leuk Res 2009 33 1718 1722 10.1016/j.leukres.2009.06.025 19625084
13. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Steiner M, Neri D, Clin Cancer Res 2011 17 6406 6416 10.1158/1078-0432.CCR-11-0483 22003068
14. Anti-tenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Reardon DA, Zalutsky MR, Bigner DD, Expert Rev Anticancer Ther 2007 7 675 687 10.1586/14737140.7.5.675 17492931 (Pubitemid 46805563)
15. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Ko HY, Choi KJ, Lee CH, Kim S, Biomaterials 2011 32 1130 1138 10.1016/j.biomaterials.2010. 10.034 21071077
16. Tumor targeting by an aptamer. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG, J Nuclear Med 2006 47 668 678 (Pubitemid 46768469)
17. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G, Chiquet-Ehrismann R, Cancer Res 2007 67 9169 9179 10.1158/0008-5472.CAN-07-0666 17909022 (Pubitemid 47535903)
18. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, Tornillo L, Terracciano L, Chiquet-Ehrismann R, Ruegg C, Seelentag W, Int J Cancer 2008 122 2454 2461 10.1002/ijc.23417 18306355 (Pubitemid 351590477)
19. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. Martina E, Degen M, Ruegg C, Merlo A, Lino MM, Chiquet-Ehrismann R, Brellier F, FASEB J 2010 24 778 787 10.1096/fj.09-140491 19884327
20. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Leprini A, Querze G, Zardi L, Perspect Dev Neurobiol 1994 2 117 123 7530138
21. Dermo-epidermal separation is associated with induced tenascin expression in human skin. Schenk S, Bruckner-Tuderman L, Chiquet-Ehrismann R, Br J Dermatol 1995 133 13 22 7545419
22. Murine tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development. Scherberich A, Tucker RP, Samandari E, Brown-Luedi M, Martin D, Chiquet-Ehrismann R, J Cell Sci 2004 117 571 581 10.1242/jcs.00867 14709716 (Pubitemid 38240198)
23. Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Galler K, Junker K, Franz M, Hentschel J, Richter P, Gajda M, Göhlert A, von Eggeling F, Heller R, Giavazzi R, Neri D, Kosmehl H, Wunderlich H, Berndt A, Histochem Cell Biol 2012 137 195 204 10.1007/s00418-011-0886-z 22075565
24. Expression of tenascin-C and its isoforms in the breast. Guttery DS, Shaw JA, Lloyd K, Pringle JH, Walker RA, Cancer Metastasis Rev 2010 29 595 606 10.1007/s10555-010-9249-9 20814719
25. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Brack SS, Silacci M, Birchler M, Neri D, Clin Cancer Res 2006 12 3200 3208 10.1158/1078-0432.CCR-05-2804 16707621 (Pubitemid 43837370)
26. A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, Gonzalez-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C, Clin Cancer Res 2011 17 7732 7742 10.1158/1078-0432.CCR-11-1203 22028492
27. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, Gonzalez-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F, Eur J Cancer 2010 46 2926 2935 10.1016/j.ejca.2010.07.033 20797845
28. The adhesion modulating properties of tenascin-W. Brellier F, Martina E, Chiquet M, Ferralli J, van der Heyden M, Orend G, Schittny JC, Chiquet-Ehrismann R, Tucker RP, Int J Biol Sci 2012 8 187 94 22211116
29. A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Berndt A, Köllner R, Richter P, Franz M, Voigt A, Berndt A, Borsi L, Giavazzi R, Neri D, Kosmehl H, Histochem Cell Biol 2010 133 467 75 10.1007/s00418-010-0685-y 20237793
30. Tissue repair and stem cell renewal in carcinogenesis. Beachy PA, Karhadkar SS, Berman DM, Nature 2004 432 324 331 10.1038/nature03100 15549094 (Pubitemid 39551660)
31. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M, Oncogene 2010 29 6115 6124 10.1038/onc.2010.350 20729912
32. Twisted tango: brain tumor neurovascular interactions. Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN, Nat Neurosci 2011 14 1375 1381 10.1038/nn.2955 22030548
33. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A, Sotiropoulou PA, Loges S, Lapouge G, Candi A, Mascre G, Drogat B, Dekoninck S, Haigh JJ, Carmeliet P, Blanpain C, Nature 2011 478 399 403 10.1038/nature10525 22012397
34. A perivascular niche for brain tumor stem cells. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ, Cancer Cell 2007 11 69 82 10.1016/j.ccr.2006.11.020 17222791 (Pubitemid 46054518)
35. The perivascular niche microenvironment in brain tumor progression. Charles N, Holland EC, Cell Cycle 2010 9 3012 3021 10.4161/cc.9.15.12710 20714216